Medical Crossfire®: Multidisciplinary Case-Based Discussions – Optimizing Diagnosis and Treatment of IBS-C and CIC

Released On
November 30, 2020

Expires On
November 30, 2021

Media Type
Internet

Completion Time
90 minutes

Specialty
Gastroenterology, Hospitalist, Primary Care

Topic(s)
IBS

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)
  • Nurses — 1.5 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This online educational activity is directed toward primary care physicians, gynecologists, gastroenterologists, nurse practitioners, physician assistants, and primary care physicians. Additional health care professionals who are involved in the care of patients with IBS-C/CIC will also be invited to participate.

Program Overview

Medical Crossfire®, one of PER®’s signature educational formats, is a video-based program in which a panel of distinguished experts engage in spirted discussions and debates on a particular clinical topic. In this activity, 4 key thought leaders explore the latest data regarding current and emerging therapeutic strategies for the management of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This lively discussion will help place new developments into clinical context to help you optimize care for your patients with these disorders.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the epidemiology, pathophysiology, and burden of IBS-C and CIC
  • Assess clinical presentation and diagnosis of IBS-C and CIC
  • Evaluate the efficacy and safety data of current and emerging therapies in the care of patients with IBS-C and CIC

Faculty

Brooks D. Cash, MD, AGAF, FACG, FACP, FASGE

Brooks D. Cash, MD, AGAF, FACG, FACP, FASGE

Chief, Gastroenterology, Hepatology, and Nutrition
Dan and Lillie Sterling Professor of Medicine
McGovern Medical School at UTHealth
Director, Ertan Digestive Disease Center
Memorial Hermann Hospital, Texas Medical Center
Houston, TX

Darren M. Brenner, ND, FACG, AGAF

Darren M. Brenner, ND, FACG, AGAF

Associate Professor of Medicine and Surgery
Irene D. Pritzker Foundation Research Scholar
Director, Neurogastro Motility and Functional Bowel Programs
Director, Motts Tonelli GI Physiology Lab
Feinberg School of Medicine
Northwestern University
Chicago, IL

Maia Kayal, MD

Maia Kayal, MD

Assistant Professor, Dr. Henry D. Janowitz Division of Gastroenterology
Icahn School of Medicine at Mount Sinai
New York, NY

ddd

Charles Vega, MD, FAAFP

Health Sciences Clinical Professor
Department of Family Medicine
Associate Dean, Culture and Community Education
Director, UC Irvine Program in Medical Education for the Latino Community
UC Irvine School of Medicine
University of California, Irvine
Irvine, CA

Accreditation Statement

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.50 Contact Hours.

Disclosures of Conflicts of Interest

In accordance with ACCME guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Brooks D. Cash, MD, AGAF, FACG, FACP, FASGE

  • Consultant: AbbVie, Salix Pharmaceuticals, Alfasigma USA, Takeda
  • Speakers Bureau: AbbVie, Salix Pharmaceuticals, Alfasigma USA, Takeda

Darren M. Brenner, ND, FACG, AGAF

  • Consultant and Speakers Bureau: Arena Pharmaceuticals, Alfasigma USA, Bayer Healthcare, Allergan (AbbVie), Ironwood Pharmaceuticals, Salix Pharmaceuticals, Takeda, Alnylam Pharmaceuticals
  • Other: Unrestricted gift for research from the Irene D. Pritzker Foundation

Maia Kayal, MD

  • No relevant financial relationships with commercial interests to disclose.

Charles Vega, MD, FAAFP

  • No relevant financial relationships with commercial interests to disclose.

The staff of Physicians’ Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Complete the activity (including pre- and postactivity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.